ASH 2014 Abstract 673 - Hodgkin's Lymphoma

Hodgkin’s Lymphoma

ASH 2014 Abstract 673. The Aethera Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma

Craig H. Moskowitz, MD et al.

Background: For the past 20 years, high-dose therapy plus autologous stem cell transplant (ASCT) has been the standard of care for patients (pts) with chemosensitive relapsed/refractory Hodgkin lymphoma (HL), providing a cure for approximately 50% of pts (Sureda 2005). Despite optimization of salvage chemotherapy, supportive care, and pt selection, improvements in outcomes post-ASCT have plateaued, likely due to disease progression (PD) in pts with pre-salvage therapy risk factors. The majority of pts with multiple risk factors will progress post-ASCT and novel therapy is urgently needed. Brentuximab vedotin (ADCETRIS®) comprises an anti-CD30 antibody conjugated by a protease-cleavable linker to a microtubule-disrupting agent, monomethyl auristatin E (MMAE), and has an objective response rate of 75% in relapsed or refractory HL. The AETHERA trial was initiated to evaluate whether early treatment with brentuximab vedotin post-ASCT can prevent progression in pts with HL (ClinicalTrials.gov #NCT01100502).

Results: A total of 329 pts were randomized at 78 sites in the United States and Europe. Of the 329 enrolled pts, 327 received study treatment. The median age was 32 years (range, 18–76) and 53% were male. The median number of prior systemic therapies (frontline and salvage) was 2 (range, 2–8); 47% of pts received more than 2 prior systemic therapies. Response to salvage therapy pre-ASCT was CR: 137 pts (42%), PR: 112 pts (34%), and stable disease (SD): 80 pts (24%). Prior to pre-ASCT salvage therapy, 106 pts (32%) had extranodal involvement and 87 pts (26%) had B symptoms. Prior to ASCT, 110 pts (33%) were PET negative, 116 pts (35%) were PET-positive and PET status was unknown for 103 pts (31%). Overall, 78% of pts had multiple risk factors for progression.

All pts had completed or discontinued study treatment as of August 2013. The median number of treatment cycles was 15, and 159 pts (49%) received 16 cycles. Reasons for treatment discontinuation were: PD: 93 pts (28%), adverse event (AE): 61 pts (19%), patient decision: 15 pts (5%), and investigator decision: 1 pt (<1%). At the time of this analysis (June 2014), the median follow-up time from randomization was 24.4 mos (range, 0–43 mos). For the pooled study population at 24 mos, the Kaplan Meier estimates were 54% (95% CI: 47%, 60%) for PFS and 88% (95% CI: 84%, 91%) for OS. Of the 50 deaths, 8 occurred prior to PD.

AEs of any grade in >15% of pts were peripheral sensory neuropathy (36%), upper respiratory tract infection (25%), neutropenia (24%), fatigue (21%), cough (19%), and pyrexia (17%). Grade 3 or higher AEs in ≥10 pts were neutropenia (20%), peripheral sensory neuropathy (6%), thrombocytopenia (3%), and peripheral motor neuropathy (3%). As assessed by a Standardised MedDRA Query, 144 pts (44%) had treatment-emergent events of peripheral neuropathy (PN). Grade 3 PN was reported for 23 pts (7%) and was mostly sensory; no Grade 4 events were observed. Resolution or at least 1 grade of improvement in PN has occurred in 80% of pts with neuropathy events; the median time to resolution or improvement was 11.7 weeks (range, 0.1–128.0 weeks).

Conclusions: Based on analysis of blinded pooled efficacy data, the estimated 2-year PFS rate was 54% and the estimated 2 year OS rate was 88%. The most common reason for treatment discontinuation was disease progression. The primary analysis for the study will be performed in September 2014 and unblinded efficacy and safety data will be publicly presented for the first time at the conference.

 

CARE Faculty Canadian Perspective:

Brentuximab vedotin is the first novel agent approved for the treatment of relapsed and refractory Hodgkin Lymphoma (HL) and is a standard of care choice in patients who have relapsed after autologous stem cell transplant (ASCT). The AETHERA study tests the concept of using maintenance with this antibody-drug conjugate in patients post ASCT. The primary endpoint of the study was PFS and this trial showed the experimental arm of Brentuximab maintenance was superior to observation with a hazard ratio of 0.57 (p<0.001, median PFS 65% vs 45%). Despite this improvement in PFS, there was no improvement in OS with current follow-up. Neuropathy and neutropenia are important adverse events in the brentuximab arm that could have contributed to early treatment discontinuation and possible decrements in QoL. This study shows a significant improvement in PFS for maintenance post-ASCT with brentuximab vedotin in patients with relapsed/refractory HL and should improve cure rates in in this setting.

Related Abstracts of Interest